PEPTIDEDOSAGE

Eloralintide Dosage Chart

Medically reviewed June 21, 2026 · Page updated November 21, 2026

TYPICAL RESEARCH DOSE

1–9 mg once weekly subcutaneously (Phase 2 trial range)

30 mg vial + 3 mL bacteriostatic water

10 mg/mL · 1 unit = 100 mcg on a U-100 syringe

PHASE	DOSE PER INJECTION	UNITS (PER INJECTION)
Weeks 1-4 — initiation (1 mg)	1000 mcg (1 mg)	10 units (0.10 mL)
Weeks 5-8 — first step-up (3 mg)	3000 mcg (3 mg)	30 units (0.30 mL)
Weeks 9-12 — mid maintenance (6 mg)	6000 mcg (6 mg)	60 units (0.60 mL)
Week 13+ — top trial dose (9 mg)	9000 mcg (9 mg)	90 units (0.90 mL)

Eloralintide dose to syringe units, by vial size

U-100 insulin syringe: 100 units = 1 mL.

DOSE	30 MG VIAL + 3 ML (10 MG/ML)
1 mg	10 units (0.1 mL)
3 mg	30 units (0.3 mL)
6 mg	60 units (0.6 mL)
9 mg	90 units (0.9 mL)

STORAGE

Lyophilized powder stored frozen at -20 °C, protected from light. Reconstituted solution refrigerated at 2–8 °C and used within about 4 weeks. Avoid freeze-thaw cycling of the mixed solution; do not shake.

Educational reference only, not medical advice. Figures restate the research protocol published at the address above.